Human prostate cell lines in cancer treatment
US7438922B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 23, 2004 |
| Grant date | Oct 21, 2008 |
| Priority date | — |
| Expiry date | Oct 27, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/884
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Combinations of cell lines are provided for allogeneic immunotherapy agents in the treatment of cancer. Cancer vaccines generally have been limited to the use of cells that contain at least some tumor specific antigens (“TSAs”) and/or tumor associated antigens (“TAAs”) having shared identity with antigens in a targeted tumor. In such cases, tumor cells often are utilized as a starting point on the premise that only tumor cells will contain TSAs or TAAs or relevance, and the tissue origins of the cells are matched to the tumor site in patients. A primary aspect of the invention is the use of immortalized normal, non-malignant cells, in combination with primary and/or metastatic tumor cells, as the basis of an allogeneic cell cancer vaccine. Normal cells do not posses TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines when administered in combination with primary and/or metastatic tumor cells. More surprisingly, a three way combination of cells obtained from metastasized cells, non metastasized tumor and cells from a normal cell line provided good therapy. For prostate cancer, for example, a vaccine may be based …
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.